Chronic Cough Attributed to Reflux: Whether an Empiric PPI Trial Still Holds Up
Months of cough with no clear pulmonary or allergic explanation land on reflux as a plausible cause — but the randomized evidence for empiric PPI therapy specifically for chronic cough is nearly as mixed as it is for laryngopharyngeal reflux, and this patient's own denial of typical reflux symptoms adds a real, separate wrinkle.
Alan G., 55, has spent most of the past four months trying to teach his weekly community woodworking class over a cough he can't seem to shake, apologizing to students between demonstrations and half-joking that he's become the workshop's least convincing safety example. His primary care physician has already worked through a reasonable standard evaluation: chest X-ray normal, spirometry and PFTs unremarkable, no smoking history, ACE inhibitor not part of his medication list, and allergy testing negative for anything explaining a cough this persistent. He specifically denies heartburn, regurgitation, or any typical reflux symptom at all — which matters, because reflux-associated cough is understood to sometimes occur without the classic symptoms that would otherwise point toward it, but that absence also removes one of the stronger pieces of supporting evidence a clinician would otherwise have going into an empiric trial.
Chronic cough attributed to reflux is proposed to work through a vagally-mediated esophagobronchial reflex, distinct from direct aspiration, which is part of why it can occur without overt heartburn. But the randomized, placebo-controlled trial evidence specifically testing empiric PPI therapy for chronic cough has been nearly as disappointing as the parallel literature in laryngopharyngeal reflux — several trials, including ones enrolling patients without confirmed reflux on testing, have failed to show a clear benefit over placebo, and the ACG reflux guideline (Katz and colleagues) advises against empiric PPI therapy for chronic cough in patients without typical reflux symptoms or confirmed reflux on testing, favoring a more targeted diagnostic approach instead.
There is a wrinkle in those negative trials. They mostly enrolled patients broadly, without requiring confirmed reflux on testing first, which is part of why current guidance has shifted toward testing rather than trialing — the negative result may reflect diluting true reflux-cough patients into a much larger group who never had reflux driving their cough at all, an argument for confirming the diagnosis first rather than evidence that reflux-associated cough itself doesn't respond to acid suppression when it's the actual cause.
A guideline that has moved away from the empiric trial
I'd go straight to confirmatory testing rather than an empiric PPI trial. Current cough-management guidelines have specifically moved toward recommending against a blind empiric trial in patients without other reflux symptoms or confirmed reflux on testing — and Alan denies heartburn or regurgitation entirely, which is exactly the population that guidance is talking about.
I take the guideline seriously, and I'm not going to argue the trial data is strong — it isn't. But reflux-associated cough without classic symptoms is a real, described clinical pattern, working through a vagal reflex rather than direct aspiration, which is part of why it can present exactly like this. I'd still offer a short, defined empiric trial as a reasonable option before committing him to pH-impedance testing, which isn't itself risk-free or trivial to arrange.
If it's genuinely time-limited with a real stopping point, I don't think that conflicts with the guideline's actual concern, which is open-ended empiric therapy in a population unlikely to benefit.
That's the piece I want to make sure doesn't get lost, whichever path you two land on: if we do try an empiric trial, it needs a genuine, dated stopping point and a planned re-evaluation, not an assumption that it becomes permanent because he's already on it and reluctant to stop something that might be helping. Given how negative the guideline-level evidence is here, though, I'd lean toward Alan's stated preference to avoid another months-long trial-and-error cycle and go straight to confirmatory testing.
Agreed: ambulatory pH-impedance testing scheduled rather than an empiric PPI trial, with a parallel re-evaluation for cough-variant asthma given the negative population-level reflux-attribution data and his complete absence of typical reflux symptoms.
A targeted PPI trial becomes genuinely evidence-supported rather than empiric, with confirmatory testing removing the diagnostic ambiguity that made the guideline caution against a blind trial.
Reflux is set aside as the likely cause, and pulmonary workup for cough-variant asthma or other etiologies proceeds without the PPI question needing to be revisited.